A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases

Abstract

Many in the scientific community are concerned about the potential increase in prevalence of insect-borne diseases such as Chagas disease, Chikungunya, dengue fever, malaria, and Zika in the United States and around the world. Beyond vaccines and drugs to prevent and treat these diseases, a comprehensive approach to fighting these diseases should include control of disease-carrying vectors, such as mosquitoes. Vector-control methods, such as using insecticides to treat bed nets and spray the walls of homes, have prevented millions of deaths from malaria. However, mosquitoes are becoming resistant to insecticides, and no new class of insecticides for vector control has been introduced in decades. We recommend the creation of a new type of incentive for the development and commercialization of safe new insecticides: a Vector Expedited Review Voucher, to be awarded to a sponsor that introduces a novel insecticide for public health use. The voucher could be redeemed to expedite registration of a second, more profitable, product by the US Environmental Protection Agency.

Pyrethroid-Derived Acids and Alcohols: Bioactivity and Synergistic Effects on Mosquito Repellency and Toxicity

“…Due to the difficulties that exist in registering new synthetic chemicals, , attempts to synergize currently available compounds may be a viable alternative. Insect repellent studies have explored combining different plant essential oils in the search for synergistic effects, − but the specific compounds responsible for synergizing repellency were not identified.…”

From Research to the Bedside: Challenges for Pediatric Academic Researchers

“…It is important to note that parent/patient groups have played a major role in expanding this legislation (eg, 2016 Creating Hope Act). Sale of these vouchers, each of which represents the development of an important treatment, has already generated >$1 billion 5 . These sales have financially benefited both pharmaceutical companies as well as academic institutions while generating approved treatments for a range of rare, neglected, or pediatric-specific conditions.…”

Possibilities for rationally exploiting co-evolution in addressing resistance to insecticides, and beyond

“…Plasmodium falciparum. IVCC is currently led by N. Hamon, who is also pursuing new approaches for registration and approval of public health-related chemistry, particularly against vector-borne pathogens, through an expedited review procedure [13]. The design and development process of IVCC is advised by an External Scientific Advisory Committee (ESAC1) chaired by the author, J. Pickett and upon which J. Bloomquist (to whom this paper is dedicated) has prominently served.…”